Abstract
Background
Ischemic heart disease has a great impact on morbidity and mortality in type2 diabetes mellitus patients. Type2Diabetes Mellitus (Type 2D.M) is risk factor for coronary atherosclerosis. N-acetyl-β-D-glucosaminidase (NAG) is an enzyme present in humans (IHD) in patients suffering from type 2 DM.
Patients and methods
cross-sectional study included 84 subjects; 21 healthy individuals, 21 patients with IHD; 21 with type 2 DM and 21 with type2DM with IHD, subjected to history taking, clinical examination, liver function tests, postprandial blood sugar, HbA1c, lipid profile, ECG, echocardiography, cardiac catheterization and carotid Doppler ultrasound. and N-acetyl –B-D-glucosaminidase level measurement
Results
There are a statistically significant differences between our groups as regard basic and laboratory data. There are differences between control group and diabetic group regarding WBCS (P=0.028), urea (p < 0.001), creatinine (p=0.003). AST,fasting, 2hour postprandial blood sugar and HBA1C (p < 0.001). There is a difference regarding NAG (p < 0.001). There are direct correlations between NAG and BMI, SBP, DBP, WBCS,, triglycerides, fasting, 2 hours postprandial blood sugar and HbA1c. The best cutoff of serum NAG in diagnosis of ischemia in diabetic patients is > 0.692 U/L, AUC of 0.949, sensitivity of 95% and specifcity of 90.91%. The best cutoff of serum NAG in diagnosis of ischemia in diabetic patients is > 6.77 U/L, AUC of 0.884, sensitivity of 90.48% and specifcity of 95.24%.
Conclusion
Level of serum N acetyl β D-glucosaminidase increases in type diabeticsmsuffering from ischemic heart disease.